+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Levodopa"

Levodopa - Global Strategic Business Report - Product Thumbnail Image

Levodopa - Global Strategic Business Report

  • Report
  • August 2025
  • 377 Pages
  • Global
From
From
Anti-Parkinson's Drugs: Global Markets to 2030 - Product Thumbnail Image

Anti-Parkinson's Drugs: Global Markets to 2030

  • Report
  • July 2025
  • 134 Pages
  • Global
From
From
Parkinson's Disease Global Market Report 2025 - Product Thumbnail Image

Parkinson's Disease Global Market Report 2025

  • Report
  • January 2025
  • 175 Pages
  • Global
From
Catecholamines Global Market Report 2025 - Product Thumbnail Image

Catecholamines Global Market Report 2025

  • Report
  • July 2025
  • 175 Pages
  • Global
From
Anti-Parkinson Drugs Market Report 2025 - Product Thumbnail Image

Anti-Parkinson Drugs Market Report 2025

  • Report
  • April 2025
  • 175 Pages
  • Global
From
Episodic Ataxia Treatment Market Report 2025 - Product Thumbnail Image

Episodic Ataxia Treatment Market Report 2025

  • Report
  • April 2025
  • 200 Pages
  • Global
From
Loading Indicator

Levodopa is a drug used to treat Parkinson's disease, a neurological disorder that affects movement. It is a dopamine precursor, meaning it is converted into dopamine in the brain, which helps to reduce the symptoms of Parkinson's. Levodopa is usually taken in combination with other drugs, such as carbidopa, to increase its effectiveness. It is one of the most commonly prescribed drugs for Parkinson's, and is often the first line of treatment. Levodopa is a part of the larger Central Nervous System (CNS) drug market, which includes drugs used to treat a variety of neurological disorders. The CNS drug market is highly competitive, with many different companies offering various treatments. Some of the companies in the Levodopa market include Merck, Novartis, Teva Pharmaceuticals, and Sun Pharmaceuticals. Show Less Read more